www.sunpharma.com Open in urlscan Pro
2606:4700::6812:114d  Public Scan

Form analysis
1 forms found in the DOM

GET https://sunpharma.com/

<form role="search" method="get" class="et-search-form" action="https://sunpharma.com/">
  <input type="search" class="et-search-field" placeholder="Search …" value="" name="s" title="Search for:">
</form>

Text Content

 * About Us
   * About Sun Pharma
   * Vision & Values
   * Milestones & Recognitions
   * Board of Directors
   * Innovation
   * Quality
 * Products
 * Responsibility
   * CSR
   * Sustainability
   * Environment, Health and Safety (EHS)
   * Covid-19
 * Investors
   * Disclosures under Regulation 46
     * Details of Business
     * Policies
     * Financial Information
       * Board Meeting & Financial Results
       * Annual Reports
     * Shareholding Pattern
     * Quarterly Financials, Transcripts & Earnings Call Recordings
     * Investor Presentations
     * Newspaper Advertisements
     * Annual Reports of Subsidiary Companies
     * Disclosure Under Regulation 30
     * Secretarial Compliance Report
     * Credit Rating
     * Investor Contact
     * Annual Return
     * Committees of the Board
   * Financials
   * Investor Presentations
   * Annual Reports
   * Annual Reports of Subsidiary Companies
   * Shareholders’ Information
     * Stock Price Information
     * Dividend History
     * Unclaimed Dividend
     * Statutory Communications
     * Scheme of Arrangement
     * Policies
     * Buyback 2020 Daily Reports
     * Details of Shares to IEPF
       * Procedure to claim refund from IEPF
       * Details of Equity Shares liable for transfer to IEPF
       * Details of Equity Shares transfered to IEPF
       * IEPF-2
     * Credit Rating
     * Memorandum of Association
     * Investor Services
     * FAQs
   * Archives
     * Sun Pharma – Ranbaxy Merger
     * Ranbaxy Archives
       * Quarterly Results
       * Corporate Governance
       * Annual Reports
       * Presentations
       * Shareholding Pattern
       * Unclaimed Dividend
   * Committees of the Board
 * Media
   * Press Releases
   * Stories
   * Media Contacts
 * Careers
 * Worldwide
   * North America
     * USA
     * Canada
     * Mexico
   * South America
     * Brazil
     * Peru
   * Asia Pacific
     * India
     * Bangladesh
     * Thailand
     * Malaysia
     * Myanmar
     * Sri Lanka
     * Japan
     * China
   * Europe
     * Denmark
     * Finland
     * France
     * Germany
     * Hungary
     * Italy
     * Norway
     * Poland
     * Romania
     * Spain
     * Sweden
     * Switzerland
     * The Netherlands
     * The United Kingdom & Ireland
   * Africa
     * Morocco
     * Nigeria
     * South Africa
   * Oceania
     * Australia & New Zealand
   * CIS
     * Russia
     * Ukraine
 * Contact Us


Select Page
 * About Us
   * About Sun Pharma
   * Vision & Values
   * Milestones & Recognitions
   * Board of Directors
   * Innovation
   * Quality
 * Products
 * Responsibility
   * CSR
   * Sustainability
   * Environment, Health and Safety (EHS)
   * Covid-19
 * Investors
   * Disclosures under Regulation 46
     * Details of Business
     * Policies
     * Financial Information
       * Board Meeting & Financial Results
       * Annual Reports
     * Shareholding Pattern
     * Quarterly Financials, Transcripts & Earnings Call Recordings
     * Investor Presentations
     * Newspaper Advertisements
     * Annual Reports of Subsidiary Companies
     * Disclosure Under Regulation 30
     * Secretarial Compliance Report
     * Credit Rating
     * Investor Contact
     * Annual Return
     * Committees of the Board
   * Financials
   * Investor Presentations
   * Annual Reports
   * Annual Reports of Subsidiary Companies
   * Shareholders’ Information
     * Stock Price Information
     * Dividend History
     * Unclaimed Dividend
     * Statutory Communications
     * Scheme of Arrangement
     * Policies
     * Buyback 2020 Daily Reports
     * Details of Shares to IEPF
       * Procedure to claim refund from IEPF
       * Details of Equity Shares liable for transfer to IEPF
       * Details of Equity Shares transfered to IEPF
       * IEPF-2
     * Credit Rating
     * Memorandum of Association
     * Investor Services
     * FAQs
   * Archives
     * Sun Pharma – Ranbaxy Merger
     * Ranbaxy Archives
       * Quarterly Results
       * Corporate Governance
       * Annual Reports
       * Presentations
       * Shareholding Pattern
       * Unclaimed Dividend
   * Committees of the Board
 * Media
   * Press Releases
   * Stories
   * Media Contacts
 * Careers
 * Worldwide
   * North America
     * USA
     * Canada
     * Mexico
   * South America
     * Brazil
     * Peru
   * Asia Pacific
     * India
     * Bangladesh
     * Thailand
     * Malaysia
     * Myanmar
     * Sri Lanka
     * Japan
     * China
   * Europe
     * Denmark
     * Finland
     * France
     * Germany
     * Hungary
     * Italy
     * Norway
     * Poland
     * Romania
     * Spain
     * Sweden
     * Switzerland
     * The Netherlands
     * The United Kingdom & Ireland
   * Africa
     * Morocco
     * Nigeria
     * South Africa
   * Oceania
     * Australia & New Zealand
   * CIS
     * Russia
     * Ukraine
 * Contact Us


 * About
 * Products
 * PVG – Medicine Safety Information

 * About
 * Products
 * PVG – Medicine Safety Information


SOUTH AFRICA







We are ranked amongst the Top eight generic pharmaceutical companies in South
Africa, where we are engaged in the sales and distribution of generic
prescription, over-the-counter (OTC) and originator prescription products. We
also offer generic anti-retroviral (ARV) medicines to needy patients in Southern
Africa, supporting national governments in their effort to control the AIDS
epidemic.

We have a state-of-the-art production facility in Roodepoort that manufactures
analgesics, cold, cough & flu preparations, anti-histamines, anti-hypertensives,
CNS medicines, vitamins & minerals, and a comprehensive range of
over-the-counter (OTC) products. The products are manufactured in various dosage
forms including tablets, capsules, oral liquids, creams and gargles. These are
marketed in the South African as well as neighbouring markets. The facility is
equipped with the latest technology, meets international specifications and
conforms to cGMP standards. It is designed to meet local regulatory requirements
(SAHPRA – South African Health Products Regulatory Authority) and complies with
PIC/S standards (Pharmaceutical Inspection Convention & Pharmaceutical
Inspection Co-operation Scheme).


CONTACT

Ranbaxy (S.A.) (Pty) Ltd.,
Ground Floor,
Tugela House,
Riverside Office Park,
1303 Heuwel Avenue,
Centurion,
Pretoria,
RSA

+27 12 643 2000
+27 12 643 2003
0866164639
shailesh.somvanshi@sunpharma.com


 * About Sun Pharma
   * Vision & Values
   * Milestones & Recognitions
 * Operations
   * Products
   * Innovation
   * Quality
 * Investors
   * Financials
   * Annual Reports
   * Shareholders Information
   * Online Dispute Resolution
 * Work with us
   * Careers
   * Current Openings
 * Quick Links
   * Contact Us
   * Partner with us
   * Adverse Events

 * Facebook
 * Twitter
 * Google
 * Instagram

Copyright © Sun Pharmaceutical Industries Ltd.       Privacy Policy | Disclaimer

We use cookies on our website to give you the most relevant experience by
remembering your preferences and repeat visits. By clicking “Accept”, you
consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent
Close

PRIVACY OVERVIEW

This website uses cookies to improve your experience while you navigate through
the website. Out of these, the cookies that are categorized as necessary are
stored on your browser as they are essential for the working of basic
functionalities of the ...
Necessary
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly.
This category only includes cookies that ensures basic functionalities and
security features of the website. These cookies do not store any personal
information.

Non-necessary
Non-necessary

Any cookies that may not be particularly necessary for the website to function
and is used specifically to collect user personal data via analytics, ads, other
embedded contents are termed as non-necessary cookies. It is mandatory to
procure user consent prior to running these cookies on your website.



Top

 Important Notice As per SEBI Circular No.
SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023 it is mandatory for
all the shareholders holding shares in physical form to update their KYC and
other details. Learn More



CLOSE